Research and Markets (http://www.researchandmarkets.com/research/tbk392/tinnitus) has announced the addition of the "Tinnitus - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Tinnitus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tinnitus and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AudioCure Pharma GmbH
- Auris Medical Holding AG
- Flexion Therapeutics, Inc.
- Knopp Biosciences LLC
- Merz Pharma GmbH & Co. KgaA
- Otonomy, Inc.
- SciFluor Life Sciences, LLC
- Sound Pharmaceuticals, Inc.
- Synphora AB
Drug Profiles
- acamprosate calcium
- AM-102
- AUT-00063
- AUT-3
- Drug to Activate KCNQ for Tinnitus
- esketamine hydrochloride
- gacyclidine SR
- latanoprost
- neramexane mesylate
- SF-0034
- Small Molecules for Tinnitus
- Small Molecules to Activate Kv7 for Neuropathic Pain, Epilepsy and Tinnitus
- Small Molecules To Inhibit TNF-Alpha for Tinnitus
- SPI-1005
- SPI-3005
For more information visit http://www.researchandmarkets.com/research/tbk392/tinnitus
View source version on businesswire.com: http://www.businesswire.com/news/home/20151126005518/en/
Contacts:
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals
